Insulet Co. (NASDAQ:PODD) Given Average Recommendation of “Hold” by Brokerages
Shares of Insulet Co. (NASDAQ:PODD) have received a consensus rating of “Hold” from the nineteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $161.00.
A number of analysts have issued reports on the company. ValuEngine downgraded Insulet from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. UBS Group cut Insulet from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $155.00 to $160.00 in a research report on Friday, October 4th. They noted that the move was a valuation call. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research report on Monday, October 14th. Cowen set a $165.00 target price on Insulet and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, JPMorgan Chase & Co. lifted their target price on Insulet from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th.
Shares of PODD traded up $2.70 during midday trading on Wednesday, hitting $187.96. 16,856 shares of the stock were exchanged, compared to its average volume of 442,937. The firm has a market cap of $11.45 billion, a P/E ratio of 3,749.20 and a beta of 1.00. The stock has a fifty day simple moving average of $177.48 and a 200 day simple moving average of $154.71. Insulet has a 52-week low of $71.22 and a 52-week high of $187.25. The company has a debt-to-equity ratio of 6.55, a quick ratio of 6.21 and a current ratio of 7.01.
In other Insulet news, Director John A. Fallon sold 14,525 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $181.21, for a total transaction of $2,632,075.25. Also, CEO Shacey Petrovic sold 689 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $145.69, for a total value of $100,380.41. Following the transaction, the chief executive officer now owns 94,510 shares in the company, valued at approximately $13,769,161.90. The disclosure for this sale can be found here. Insiders sold a total of 30,598 shares of company stock worth $5,346,687 in the last 90 days. 3.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. LPL Financial LLC increased its position in Insulet by 44.8% during the 2nd quarter. LPL Financial LLC now owns 7,232 shares of the medical instruments supplier’s stock worth $863,000 after purchasing an additional 2,238 shares during the period. Renaissance Technologies LLC acquired a new position in Insulet during the 2nd quarter worth approximately $17,119,000. Parametric Portfolio Associates LLC boosted its stake in shares of Insulet by 51.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 46,565 shares of the medical instruments supplier’s stock worth $5,559,000 after acquiring an additional 15,875 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of Insulet during the 2nd quarter worth approximately $693,000. Finally, Integre Asset Management LLC purchased a new stake in shares of Insulet during the 2nd quarter worth approximately $219,000.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Featured Article: How to identify percentage decliners
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.